Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

NCT02750592 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

DRUG: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

Sponsor

Novartis Pharmaceuticals